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ABSTRACT
The aim of this study was to evaluate the body mass index dependent metabolic syndrome in
severe mental illness patients in Gorgan. A total of 267 severe mental illness patients took part in
this study. The prevalence of metabolic syndrome in severe mental illness patients in different body
mass index were 6.67, 24.09 and 53.06%. There were significant differences in the mean of waist
circumference, HDL-cholesterol, triglyceride and fasting blood glucose in subjects with metabolic
syndrome in different body mass index when compared with subjects without metabolic syndrome
(p<0.05). The prevalence of high fasting glucose, low high density lipoprotein-cholesterol, high
triglyceride levels, high waist circumference and high blood pressure were 14.23, 38.57, 41.57, 32.96
and 5.24%, respectively. It shows that high triglyceride levels (41.57%) and Low HDL-cholesterol
levels (38.57%) were the most frequent characteristics in comparison to other metabolic
components. Our results show that, 26.96, 31.08, 21.35, 15.35 and 5.25% of subjects had zero, one,
two, three and four criteria for metabolic syndrome, respectively. These results show that the
prevalence of metabolic syndrome in severe mental illness patients in Gorgan is increased with
elevated body mass index. The results of this study suggest that mental illness patients are at risk
of metabolic syndrome, when the rate of body mass index increases. Risk factors such as high
triglyceride level and low HDL-cholesterol may play an important role in the occurrence of
metabolic syndrome in severe mental illness patients.
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INTRODUCTION
Metabolic Syndrome (MetS) is defined as a cluster of risk factors (glucose intolerance, obesity,
raised blood pressure and dyslipidemia) that raises cardiovascular morbidity and mortality rate
(Day, 2007). This syndrome is a global epidemic health problem (Yates et al., 2012). Overall
prevalence of the metabolic syndrome in non-diabetic subjects using WHO criteria is 15.7% in men
and 14.2% in women (Alberti et al., 2006). Also it has been reported that prevalence of this
syndrome in the world is ranging among men from 8% in India to 24% in United States while it is
ranging among women from 7% in France to 46% in India (Mattoo and Shubh, 2010). Several
studies have shown that there are the relationship between metabolic syndrome and coronary
artery   diseases  in  different  ethnic  groups,  gender,  age,  postmenopausal  women  and  different
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countries (Marjani et al., 2012a; Shahini et al., 2013; Marjani et al., 2012b; Marjani and Shahini,
2013; Marjani and Moghasemi, 2012; Takeuchi et al., 2005; Lakka et al., 2002). Pathogenesis of
metabolic syndrome is complex but two features appear to be potential causative factors: Insulin
resistance and abnormal fat distribution (central obesity). It is demonstrated that the prevalence
of  metabolic syndrome in populations with mental illness is higher than general population
(Mattoo and Shubh, 2010). Some studies documented this for patients with schizophrenia and
bipolar disorder. Similar findings were reported in psychiatric inpatients in USA, Brazil and India
(Mattoo and Shubh, 2010). In a recent large study of outpatients with psychiatric illness, it was
shown that prevalence of metabolic syndrome was 52% among them (Khatana et al., 2011). This
high prevalence is more pronounced in patients with schizophrenia (John et al., 2009) and it has
been  attributed  to  the  second  generation  antipsychotics  used  by  psychiatric  patients
(Khatana et al., 2011). Prevalence of obesity and visceral fat distribution in schizophrenic patients
is generally greater than individuals without this disorder (Toalson et al., 2004). Some studies
suggest that a significant part of the metabolic syndrome risk is inherent in the psychiatric disease
process itself (Mackin et al., 2005) but these studies are limited and more investigations are needed
to reveal this association. Based on population studies, it has been shown that an increase in the
risk of the metabolic syndrome is associated by a progressive increase in total adiposity that
assessed by Body Mass Index (BMI) (Alberti et al., 2006). It has been suggested that increasing of
BMI is an important factor in the presence of metabolic syndrome (Mattoo and Shubh, 2010). One
study showed that BMI was higher in patients with bipolar disorder than control group without
bipolar disorder (McElroy, 2009). In a study, BMI was significantly higher in patients with
concurrent schizophrenia and bipolar disease than patients with schizophrenia or bipolar disorder
alone (Khatana et al., 2011). It is suggested that metabolic syndrome should be evaluated in
psychiatrically ill patients while they approach higher body mass index (Alberti et al., 2006). The
aim of this study was to evaluate the body mass index dependent metabolic syndrome in severe
mental illness patients in Gorgan.
MATERIALS AND METHODS
The 267 Severe Mental Illness (SMI) patients took part in this study which were referred to the
psychiatric unit at 5th Azar Education Hospital of Gorgan, Faculty of Medicine, Golestan
University of Medical Sciences in Gorgan, Iran in 2014. Schizophrenia, bipolar 1 mood disorder,
major depressive disorder with psychotic features, psychotic or mood disorder defined as severe
mental illness patients. Collection of ten milliliter blood samples were carried out after a 12 h
overnight fast. Determination of biochemical parameters in serum (Fasting blood glucose, high
density lipoprotein cholesterol (HDL-cholesterol), total cholesterol and triglyceride levels) were
done with commercial kits by spectrophotometer techniques (Model JENWAY 6105 UV/VIS) in the
Metabolic Disorders Research Center. Low density lipoprotein cholesterol (LDL-cholesterol) level
was calculated by Friedewald equation. Weight of subjects was measured, when they were
minimally clothed and without shoes using digital scales. Height was measured in standing
position with the shoulder in a normal position using tape meter. Body mass index was determined,
when weight (in kilograms) divided by height (in meters squared). Normal weight was defined as
BMI  =  18.5-24.9,  Overweight  as  BMI  =  25.0-29.9  kg  mG2  and  obese  as  BMI  $30  kg  mG2
(Altekin et al., 2005). Waist circumferences were measured at the point halfway between the lower
border of ribs and the iliac crest in a horizontal plane (WHO., 1998). Systolic and diastolic blood
pressure was measured in sitting position from the right hand. Metabolic syndrome defined if
severe mental illness patients show any three or more of the criteria mentioned in Table 1,
according to the ATP III (Adult Treatment Panel III) (2001).
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Table 1: Metabolic syndrome components for the metabolic syndrome according to ATP III (adult treatment panel III)
Metabolic syndrome components Clarifying level of parameters
Waist circumference For males >102 cm and for females >88 cm
Triglyceride levels $150 mg dLG1
High-density lipoprotein levels For males <40 mg dLG1 and for females <50 mg dLG1
Blood pressure Systolic $130 mm Hg, Diastolic $85 mm Hg
Fasting glucose levels $110 mg dLG1
Statistical analysis: The statistical data analysis was carried out by SPSS-16 version software.
The data are showed as means and standard deviations and percentages. The data evaluation was
done by using independent sample t and chi-squared tests. A p-value lowers than 0.05 considered
statistically significant.
RESULTS
Table 2 shows biochemical characteristic of severe mental illness patients with and without
metabolic syndrome with BMI = 18.5-24.9 kg mG2. The mean fasting blood glucose level was
significantly higher in the severe mental illness patients with metabolic syndrome (p<0.05). The
prevalence of metabolic syndrome in these severe mental illness patients was 6.67%. Table 3 shows
biochemical characteristic of severe mental illness patients with and without metabolic syndrome
with BMI = 25-29.9 kg mG2. There were significant differences in the mean of waist circumference,
HDL-cholesterol and fasting blood glucose in subjects with metabolic syndrome, when compared
with subjects without metabolic syndrome (p<0.05). The prevalence of metabolic syndrome in
severe mental illness was 24.09%. Table 4 shows biochemical characteristic of severe mental illness
patients with and without metabolic syndrome with BMI>30 kg mG2. There were significant
differences in the mean of triglyceride, HDL-cholesterol and fasting blood glucose in subjects with
metabolic syndrome, when compared with subjects without metabolic syndrome (p<0.05). The
prevalence of metabolic syndrome in severe mental illness was 53.06%. Table 5 shows prevalence
of metabolic syndrome and the components of metabolic syndrome in severe mental illness patients.
The prevalence of high fasting glucose, low high density lipoprotein-cholesterol, high triglyceride
levels, high waist circumference and high blood pressure were shown to be 14.23, 38.57, 41.57,
32.96 and 5.24%, respectively. It shows that high triglyceride (41.57%) and Low HDL-cholesterol
levels (38.57%) were the most frequent characteristics in comparison to other metabolic
components. Table 6 shows number of subjects accomplishing the criteria of metabolic syndrome.
Our results show that 26.96, 31.08, 21.35, 15.35 and 5.25% of subjects had zero, one, two, three and
four criteria for metabolic syndrome, respectively.
DISCUSSION
The results of this study showed that prevalence of metabolic syndrome increased with
elevation of body mass index in severe mental illness patients (Table 2-4). It was revealed that
prevalence of metabolic syndrome reported 37, 60 and 75% among schizophrenic and mood disorder
patients, respectively (Heiskanen et al., 2003; Kato et al., 2003). Studies on different populations
showed that metabolic syndrome changes in populations of Hong Kong (35%), USA (28.7-60%),
Australia (54%), Canada (44.7%) and Finland (37.1%) (Heiskanen et al., 2003; Bressington et al.,
2013; Straker et al., 2003; Kato et al., 2004; John et al., 2009; Cohn et al., 2004). Studies on Asian
populations like Taiwan and Thailand showed that prevalence of metabolic syndrome in
schizophrenia patients were 22 and 20%, respectively (Littrell et al., 2003; Srisurapanont et al.,
2007)  which  was  lower  than  western  populations. Results of this study show that the prevalence
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Table 2: Biochemical characteristic of severe mental illness patients with and without metabolic syndrome with BMI=18.5-24.9 kg mG2
All severe mental Severe mental illness patients Severe mental illness patients
Parameters illness patients without metabolic syndrome with metabolic syndrome p-value
BMI (kg mG2) <25
Number of patients (%) 135.0 (100) 126.0 (93.33) 9 (6.67)
Age (years) 38.77±11.18 38.98±11.25 41.8±8.92 0.58
Waist circumference (cm) 81.73±8.57 81.41±8.67 84.4±4.15 0.44
Systolic blood pressure (mm Hg) 103.96±11.62 103.85±11.35 104.0±15.16 0.97
Diastolic blood pressure (mm Hg) 66.14±9.16 65.75±8.9 69.0±12.44 0.43
Triglyceride (mg dLG1) 134.10±70.07 132.87±70.62 189.4±41.52 0.08
Total cholesterol (mg dLG1) 160.81±47.25 161.13±47.79 164.0±48.74 0.89
HDL-cholesterol (mg dLG1) 51.30±15.18 51.29±14.96 49.4±23.41 0.78
LDL-cholesterol (mg dLG1) 82.21±41.31 82.76±41.85 76.8±46.01 0.75
Glucose (mg dLG1) 80.14±18.06 78.48±11.98 126.4±57.21 0.001
HDL: High density lipoprotein, LDL: Low density lipoprotein
Table 3: Biochemical characteristic of severe mental illness patients with and without metabolic syndrome with BMI= 25-29.9 kg mG2
All severe mental Severe mental illness patients Severe mental illness patients
Parameters illness patients without metabolic syndrome with metabolic syndrome p-value
BMI (kg mG2) = 25-29.9
Number of patients (%) 83.0 (100) 63.0 (75.90) 20.0 (24.09)
Age (years) 38.90±10.78 38.0±10.77 41.5789±10.86 0.2
Waist circumference (cm) 95.92±7.09 94.81±7.23 99.42±5.47 0.01
Systolic blood pressure (mm Hg) 107.26±12.10 106.02±10.08 110.79±17.09 0.13
Diastolic blood pressure (mm Hg) 68.80±10.34 67.5±9.51 72.63±12.17 0.057
Triglyceride (mg dLG1) 173.86±92.82 166.0±93.47 203.16±88.66 0.13
Total cholesterol (mg dLG1) 172.46±48.5 175.38±49.56 162.74±46.02 0.32
HDL-cholesterol (mg dLG1) 49.5738±15.15 51.4±15.73 43.57±11.77 0.047
LDL-cholesterol (mg dLG1) 87.33±41.11 89.7±39.15 78.42±48.02 0.2
Glucose (mg dLG1) 83.09±19.55 78.56±12.22 98.1±30.44 0.001
HDL: High density lipoprotein, LDL: Low density lipoprotein
Table 4: Biochemical characteristic of severe mental illness patients with and without metabolic syndrome with BMI >30 kg mG2
All severe mental Severe mental illness patients Severe mental illness patients
Parameters illness patients without metabolic syndrome with metabolic syndrome p-value
BMI (kg mG2)>30
Number of patients (%) 49.0 (100) 23.0 (46.94) 26.0 (53.06)
Age (years) 39.333±10.16 38.75±11.06 42.59±8.23 0.08
Waist circumference (cm) 105.72±8.51 104.20±8.06 107.04±8.85 0.28
Systolic blood pressure (mm Hg) 109.88±12.55 107.00±9.23 112.39±14.6 0.16
Diastolic blood pressure (mm Hg) 72.32±10.19 70.50±9.16 73.91±10.97 0.28
Triglyceride (mg dLG1) 96.23±88.19 144.15±82.81 212.61±81.52 0.009
Total cholesterol (mg dLG1) 186.33±44.69 176.75±30.81 194.65±53.26 0.19
HDL-cholesterol (mg dLG1) 47.41±16.09 56.75±15.75 39.30±11.5 0.001
LDL-cholesterol (mg dLG1) 102.54±46.85 90.77±40.25 112.78±50.55 0.12
Glucose (mg dLG1) 180.77±39.03 82.35±10.72 108.30±49.82 0.028
HDL: High density lipoprotein, LDL: Low density lipoprotein
Table 5: Prevalence of the components of metabolic syndrome in severe mental illness patients (N = 267)
Parameters No. %
Fasting blood sugar $110 mg dLG1 38 14.23
High density lipoprotein-cholesterol for males <40 mg dLG1 and for females <50 mg dLG1 103 38.57
Triglyceride $150 mg dLG1 111 41.57
Waist circumference for males >102 cm and for females >88 cm 88 32.96
Systolic blood pressure >130 mm Hg/diastolic blood pressure >85 mm Hg 14 5.24
Table 6: Number of subjects accomplishing the criteria of metabolic syndrome
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of metabolic syndrome in patients with normal and overweight body mass index is to be lower than
western populations (Heiskanen et al., 2003; Straker et al., 2003; Kato et al., 2004; John et al.,
2009; Cohn et al., 2004) and North American (McEvoy et al., 2005). Etiology of metabolic syndrome
in severe mental illness patients may depend on socioeconomic, nutritional status, different ethnic
groups, cultural differences, medical care and kind of life style (Hennekens, 2007; Robson and Gray,
2007). These factors may reduce susceptibility for metabolic syndrome in our area when it compares
to other populations. A study showed that central obesity, hypertension, dyslipidemia and
hyperglycemia as risk factors of cardiovascular disease were higher in severe mental illness
patients than general population (Keenan et al., 2013). Elevated fasting blood sugar and reduced
HDL-cholesterol were common with increase of body mass index in our study. High waist
circumference and high triglyceride levels were seen in overweight and obese patients when body
mass index increases. Thus, high waist circumference gives its place to high triglyceride levels with
increase of body mass index. In this study, 41.57, 38.57 and 32.96% of subjects had high triglyceride
level, low HDL-cholesterol level and high waist circumference, respectively. Some studies have
shown that there are an association between serum triglyceride and low HDL-cholesterol levels and
coronary heart disease and cardiovascular disease prevalence (Kannel et al., 1991; Assmann et al.,
1998; Vega and Grundy, 1996). Some other studies have indicated that a low HDL-cholesterol level
is associated with increased levels of serum triglycerides and high LDL-cholesterol (Austin et al.,
2000). It was reported that waist circumference is associated with increase of portal free fatty acid
levels (Zabetian et al., 2007). A study has shown that body mass index was not significantly
different between schizophrenic patients and their healthy controls (Oresic et al., 2011). A lot of
guidelines have recommended that body mass index should be assessed regularly in patients with
psychotic disorders and it is more important in patients who receive antipsychotics (McEvoy et al.,
2005). At the first 6 months after initiating treatment, body mass index was showed to be stable
(McEvoy et al., 2005). In an Australian study it was shown that in patients with bipolar disease or
schizophrenia or both together, body mass index elevated after 18 months from baseline with
receiving antipsychotic therapy in control group, but it was decreased in intervention group who
underwent exercise, changing diet and physical activity program in this period (McEvoy et al.,
2005). Body mass index was not significantly different between psychiatric outpatients who
underwent typical and atypical antipsychotic therapy (Mackin et al., 2005). There is some evidence
of ischemic damage in adult brains that had metabolic syndrome (Yates et al., 2012). Studies have
shown that individuals with metabolic syndrome have increased prevalence of intracranial
arteriosclerosis and white matter lesions. Brain’s White matter abnormalities were associated with
elevating in presence of metabolic syndrome components that could be derived by vascular risk
factors in people with metabolic syndrome (Yates et al., 2012). It is suggested that metabolic
syndrome could affect on brain integrity that is partly caused by abnormality in vascular reactivity
as it increase carotid stiffness and intima-media thickness 2. Schizoaffective, bipolar and depressive
disorders patients show elevated mortality (Lawrence et al., 2001; Taylor and MacQueen, 2006;
Harris and Barraclough, 1998). Psychiatric illness must consider as a risk factor for metabolic
syndrome to prevent occurrence of some diseases in the future. People with mental disorders,
cardiovascular disease may consider as an important risk factors. Thus, the screening of this
disease should be taken into consideration by health care service centers.
CONCLUSION
These results show that the prevalence of metabolic syndrome in severe mental illness patients
in Gorgan is increased  with  elevated  body  mass  index.  The  results  of  this  study  suggest  that
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mental illness patients are at risk of metabolic syndrome when the rate of body mass index
increases. Risk factors such as high triglyceride level and low HDL-cholesterol are the most
prevalent of metabolic syndrome components. These risk factors may play an important role in the
occurrence of metabolic syndrome in severe mental illness patients.
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